Verano Holdings (VRNO) Non-Current Assets (2021 - 2026)
Verano Holdings' (VRNO) quarterly Non-Current Assets came in at $29.0 million in Q1 2026, down 0.65% year-on-year from $29.2 million in Q1 2025, and down 2.63% on a QoQ basis from $29.8 million in Q4 2025.
Verano Holdings (VRNO) Non-Current Assets (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Non-Current Assets data on file, last reported at $29.0 million in Q1 2026.
- On a quarterly basis, Non-Current Assets fell 0.65% year-over-year to $29.0 million in Q1 2026; TTM through Mar 2026 was $29.0 million, a 0.65% decrease from a year earlier, with the FY2025 full-year figure at $29.8 million, up 12.23% from the prior year.
- Non-Current Assets for Q1 2026 stood at $29.0 million, down from $29.8 million in the prior quarter.
- Over the last five years, Non-Current Assets for VRNO reached as high as $95.4 million in Q3 2022 and fell as low as $21.7 million in Q3 2023.
- Historically, Non-Current Assets has averaged $42.1 million across 5 years, with a median of $29.0 million in 2025.
- Across the five-year window, Non-Current Assets tumbled 77.28% in 2023 and increased 15.95% in 2024, its largest moves.
- Year by year, Non-Current Assets stood at $72.1 million in 2022, then tumbled by 60.37% to $28.6 million in 2023, then dropped by 7.05% to $26.6 million in 2024, then increased by 12.23% to $29.8 million in 2025, then declined by 2.63% to $29.0 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $29.0 million in Q1 2026, $29.8 million in Q4 2025, and $28.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 29.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.02 Mn |
| Dec 31, 2025 | 29.80 Mn |
| Sep 30, 2025 | 28.22 Mn |
| Jun 30, 2025 | 28.98 Mn |
| Mar 31, 2025 | 29.21 Mn |
| Dec 31, 2024 | 26.56 Mn |
| Sep 30, 2024 | 25.13 Mn |
| Jun 30, 2024 | 26.27 Mn |
| Mar 31, 2024 | 26.73 Mn |
| Dec 31, 2023 | 28.57 Mn |
| Sep 30, 2023 | 21.67 Mn |
| Jun 30, 2023 | 81.82 Mn |
| Mar 31, 2023 | 82.67 Mn |
| Dec 31, 2022 | 72.08 Mn |
| Sep 30, 2022 | 95.36 Mn |
| Dec 31, 2021 | 207.91 Mn |